BRENDA™ (Fuzapladib Sodium Hydrate)
In September 2018, ISK obtained manufacturing/marketing approval for this drug in Japan with the effect of “reduction of clinical signs associated with acute pancreatitis in dogs”.
Fuzapladib blocks activation of adhesion molecules (integrin) expressed on the inflammatory cell surface to prevent inflammatory cells from adhering to vascular endothelial cells and infiltrating tissue and to control exacerbation of pancreatitis. This mode of action is different from that of conventional anti-inflammatory drugs including steroids and non-steroid anti-inflammatory drugs (NSAIDs). No medicinal product for animal use with a similar action mechanism is available anywhere in the world, including Japan.
